Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development. Mol Cancer Ther; 11(3); 517–25. ©2012 AACR.

[1]  Mitchell Ho,et al.  Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin , 2005, Clinical Cancer Research.

[2]  I. Pastan,et al.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  I. Pastan,et al.  Immunotoxin treatment of cancer. , 2007, Annual review of medicine.

[4]  Jingli Zhang,et al.  Anti–Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts , 2007, Clinical Cancer Research.

[5]  Mitchell Ho,et al.  Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.

[6]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[7]  I. Pastan,et al.  Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1 , 2004, Clinical Cancer Research.

[8]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[9]  I. Pastan,et al.  Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors , 2007, Proceedings of the National Academy of Sciences.

[10]  M. Giedlin,et al.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  I. Pastan,et al.  Improving antibody affinity by mimicking somatic hypermutation in vitro , 1999, Nature Biotechnology.

[12]  B. Levine,et al.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.

[13]  Mitchell Ho,et al.  Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients , 2005, Clinical Cancer Research.

[14]  Mitchell Ho,et al.  Mesothelin targeted cancer immunotherapy. , 2008, European journal of cancer.

[15]  I. Pastan,et al.  Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. , 2007, Cancer immunity.

[16]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[17]  S. Cascio,et al.  Tumor immunology: basic and clinical advances. , 2011, Cancer research.

[18]  I. Pastan,et al.  Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers , 2010, Clinical Cancer Research.

[19]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  C. Ramos,et al.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy , 2011, Expert opinion on biological therapy.

[21]  D. Curiel,et al.  Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy , 2005, Gene Therapy.

[22]  I. Pastan,et al.  Localization of Mesothelin in Epithelial Ovarian Cancer , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[23]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  I. Pastan,et al.  Mesothelin Is Not Required for Normal Mouse Development or Reproduction , 2000, Molecular and Cellular Biology.

[25]  I. Pastan,et al.  Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. , 2010, Lung cancer.

[26]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[27]  I. Pastan,et al.  Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  P. Fisher,et al.  A Fiber-Modified Mesothelin Promoter–Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer , 2008, Clinical Cancer Research.

[29]  I. Pastan,et al.  Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Pastan,et al.  Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P , 2009, Clinical Cancer Research.

[31]  E. Jaffee,et al.  Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation , 2008, Clinical Cancer Research.

[32]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[33]  I. Pastan,et al.  Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts , 2011, Clinical Cancer Research.

[34]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[35]  Ira Pastan,et al.  Mesothelin: a new target for immunotherapy. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  R. Steinman,et al.  The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic Cells , 2009, Annals of the New York Academy of Sciences.

[37]  Anke Mayer-Bartschmid,et al.  Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models , 2011 .

[38]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[39]  Mitchell Ho,et al.  Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice , 2006, Clinical Cancer Research.

[40]  T. Wu,et al.  Control of human mesothelin-expressing tumors by DNA vaccines , 2007, Gene Therapy.

[41]  I. Pastan,et al.  Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.

[42]  N. Yamaguchi,et al.  A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. , 1994, The Journal of biological chemistry.

[43]  M. Miettinen,et al.  Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura , 2003, The American journal of surgical pathology.

[44]  M. Ziepert,et al.  Reply to K. Tay et al , 2011 .

[45]  C. Verschraegen,et al.  Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. , 2004, Anticancer research.

[46]  M. Maeda,et al.  Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. , 2010, International journal of molecular medicine.

[47]  I. Pastan,et al.  Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium , 1992, International journal of cancer.

[48]  Shenmin Zhang,et al.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer , 2008, Molecular Cancer Therapeutics.

[49]  H. Yamaue,et al.  Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. , 2011, Cancer letters.

[50]  N. Ordóñez.  Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma , 2003, Modern Pathology.